Effects of Transcutaneous Spinal Direct Current Stimulation on Mobility in Cases With Multiple Sclerosis

Multiple Sclerosis Clinical Trial

Official title:

Effects of Transcutaneous Spinal Direct Current Stimulation on Mobility in Cases With Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06110936
• Other study ID #: 09.2021.733
• Status: Completed
• Phase: N/A
• Start date: November 27, 2023
• Est. completion date: March 30, 2024

Study information

• Verified date: April 2024
• Source: Istanbul Medeniyet University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primer aim of the study is to examine the effects of the transcutaneous spinal direct current stimulation (ts-DCS) on mobility in addition to the physiotherapy program to individuals with multiple sclerosis. Our secondary aim is to show the relationship of these effects with ts-DCS through fatigue and quality of life evaluations.

Description:

Our study is carried out at Istanbul Cadde Medical Center. The patients who will participate in the study are determined according to the inclusion criteria among the patients who applied to the Multiple Sclerosis Polyclinic of Istanbul Medeniyet University Göztepe Training and Research Hospital, Department of Neurology. Transcutaneous spinal direct current will be applied to the individuals participating in our study in 20-minute sessions, 3 days a week for 2 weeks. According to the type of stimulation applied, participants are divided into two groups: experimental and control groups by simple randomization. While cathodal ts-DAU was applied to the patients in the experimental group; Sham ts-DAU is applied to patients in the control group. The same evaluations will be applied to all participants throughout the study, and the evaluations are applied before and after the intervention. The data collected as a result of the evaluations will be analyzed with SPSS version 22.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: March 30, 2024
• Est. primary completion date: March 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients diagnosed with MS and suffering from walking difficulties due to MS

• EDSS score between 2-6

• Being over 18 years old

Exclusion Criteria:

• Relapsed within the last two months

• Changed medication within 45 days

• Hospitalized in the last three months

• Had other neurological or musculoskeletal problems

• Had an obstacle to stimulation (skin problems, metal implants, etc.)

• Do not want to participate in the study individuals

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis
• Transcranial Direct Current Stimulation

Intervention

Device:
• Transcutaneous Spinal Direct Current Stimulation
Transcutaneous spinal direct current stimulation (ts-DCS), a neuromodulation technique, is one of the non-invasive brain stimulation techniques. ts-DCS occurs when a continuous and low-intensity electric current passes through electrodes with moist sponges placed on the spinal cord.

Locations

Country	Name	City	State
Turkey	Cadde Tip Merkezi	Istanbul	Kadiköy

Sponsors (1)

Lead Sponsor	Collaborator
Istanbul Medeniyet University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Timed 25-Foot Walk (T25-FW)	Timed 25 Foot Walking Test was used for objective evaluation of walking. In T25-FW, which evaluates lower extremity function, the individual is asked to walk 25 steps as quickly and safely as possible (if he/she uses a walking aid, this is done together). The time spent walking is recorded in seconds.	It will be evaluated twice: immediately before and immediately after 2 weeks treatment.
Primary	Time Up and Go (TUG)	It is a performance-based test used to evaluate functional mobility and walking speed. The person is asked to get up from the chair he/she is sitting on without support from his/her arms, walk 3 meters at a safe and normal speed, turn around, walk back, sit on the chair again, and the time is recorded in seconds (sec). The test is started with the patient's feet flat on the floor and arms resting on the armrest of the chair. Three repetitions are made and the best result is recorded.	It will be evaluated twice: immediately before and immediately after 2 weeks treatment.
Primary	Multiple Sclerosis Walking Scale-12 (MSWS-12)	It is a 12-item rating scale used to assess individuals' perspectives on the impact of their disease on their ability to walk. During the test, patients are asked to rate how much MS affects their mobility, such as standing, walking, running, and climbing stairs, on a 5-point Likert Scale (1=almost not at all, 5=extremely). A high score indicates that walking ability is affected or the patient has difficulty walking. The lowest score can be 12 and the highest score can be 60 from the test.	It will be evaluated twice:immediately before and immediately after 2 weeks treatment.
Primary	Gait Speed Assessment	Calculation of walking speed will be done by 2D video analysis method. Kinovea 2D motion analysis software (GPLv2 license, 2019) will be used for analysis. The method has validity and reliability. The videos taken with the cameras placed laterally will be uploaded to the program and the necessary calculations will be made.	It will be evaluated twice: immediately before and immediately after 2 weeks treatment.
Secondary	Fatigue Severity Scale (FSS)	The scale, which includes the experience of fatigue, its causes and its effects on daily life, consists of 9 questions and is a Likert-type scale where each question takes a value between 0 and 7. The highest score reached is 63. A score of 36 or above indicates a high perception of fatigue severity.	It will be evaluated twice: immediately before and immediately after 2 weeks treatment.
Secondary	Fatigue Impact Scale (FIS)	Fatigue Impact Scale will be used to evaluate the reflection of fatigue on daily activities in patients. This scale evaluates the physical, cognitive and social effects of fatigue in the last month with a total of 40 questions (0 = no problem, 4 = extreme). The total score ranges from 0-160, with higher scores indicating a higher degree of fatigue impact	It will be evaluated twice: immediately before and immediately after 2 weeks treatment.